BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 21591820)

  • 1. Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    Reboli AC; Rotstein C; Kett DH; Maschio M; Cartier S; Chambers R; Tarallo M
    Pharmacoeconomics; 2011 Aug; 29(8):705-17. PubMed ID: 21591820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    Auzinger G; Playford EG; Graham CN; Knox HN; Weinstein D; Kantecki M; Schlamm H; Charbonneau C
    BMC Infect Dis; 2015 Oct; 15():463. PubMed ID: 26503366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Grau S; Salavert M; Carlos Pozo Laderas J; García Vargas M; Barrueta JA; Mir N
    J Mycol Med; 2013 Sep; 23(3):155-63. PubMed ID: 23849341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
    Kett DH; Shorr AF; Reboli AC; Reisman AL; Biswas P; Schlamm HT
    Crit Care; 2011; 15(5):R253. PubMed ID: 22026929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
    Neoh CF; Liew D; Slavin M; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
    J Antimicrob Chemother; 2011 Aug; 66(8):1906-15. PubMed ID: 21628305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of anidulafungin vs fluconazole for the treatment of invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Mycoses; 2017 Nov; 60(11):714-722. PubMed ID: 28699297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    Ou HT; Lee TY; Chen YC; Charbonneau C
    BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
    Heimann SM; Cornely OA; Wisplinghoff H; Kochanek M; Stippel D; Padosch SA; Langebartels G; Reuter H; Reiner M; Vierzig A; Seifert H; Vehreschild MJ; Glossmann J; Franke B; Vehreschild JJ
    Eur J Clin Microbiol Infect Dis; 2015 Feb; 34(2):331-8. PubMed ID: 25213718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anidulafungin for the treatment of invasive candidiasis.
    Mayr A; Aigner M; Lass-Flörl C
    Clin Microbiol Infect; 2011 Mar; 17 Suppl 1():1-12. PubMed ID: 21251147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of candidemia with echinocandins: data on hospital resource use from a real world setting.
    Wade RL; Chaudhari P; Campbell RS; Hays HD; Nathanson BH; Yi J; Horn D
    J Med Econ; 2012; 15(6):1130-8. PubMed ID: 22788668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.
    van der Geest PJ; Hunfeld NG; Ladage SE; Groeneveld AB
    BMC Infect Dis; 2016 Sep; 16():490. PubMed ID: 27634140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome.
    Reboli AC; Shorr AF; Rotstein C; Pappas PG; Kett DH; Schlamm HT; Reisman AL; Biswas P; Walsh TJ
    BMC Infect Dis; 2011 Sep; 11():261. PubMed ID: 21961941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
    Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
    Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
    Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
    BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients.
    Ruhnke M; Paiva JA; Meersseman W; Pachl J; Grigoras I; Sganga G; Menichetti F; Montravers P; Auzinger G; Dimopoulos G; Borges Sá M; Miller PJ; Marček T; Kantecki M
    Clin Microbiol Infect; 2012 Jul; 18(7):680-7. PubMed ID: 22404732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
    Vazquez J; Reboli AC; Pappas PG; Patterson TF; Reinhardt J; Chin-Hong P; Tobin E; Kett DH; Biswas P; Swanson R
    BMC Infect Dis; 2014 Feb; 14():97. PubMed ID: 24559321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China.
    Chen D; Wan X; Kruger E; Chen C; Yue X; Wang L; Wu J
    J Med Econ; 2018 Mar; 21(3):301-307. PubMed ID: 29303621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
    Zilberberg MD; Kothari S; Shorr AF
    Crit Care; 2009; 13(3):R94. PubMed ID: 19545361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of invasive candidiasis: between guidelines and daily clinical practice.
    Tagliaferri E; Menichetti F
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):685-9. PubMed ID: 25818660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.